Storia in 2 fonti

Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population

A phase 3 study of Gilead’s Livdelzi has met its primary endpoint,

Raccontata da

fiercepharma.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo6 h fa

Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population

Livdelzi met phase 3 primary endpoint in PBC, expanding use to UDCA-intolerant patients showing normalized alkaline phosphatase levels. $133M Q1 2026 sales (3.3× YoY) validates Gilead's $4.3B CymaBay acquisition and market position vs Iqirvo in rare hepatic disease.

originale

benzinga.com3 h fa

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Gilead Sciences (NASDAQ:GILD)

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.

Leggi questa versione → originale

Timeline cronologica

martedì 2 giugno 2026·fiercepharma.com
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint,
martedì 2 giugno 2026·benzinga.com
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Gilead Sciences (NASDAQ:GILD)
Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.